Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.2%

Bristol-Myers Squibb (NYSE:BMY) shot up 0.2% on Tuesday . The stock traded as high as $49.47 and last traded at $49.25. 1,272,055 shares traded hands during trading, a decline of 92% from the average session volume of 15,421,163 shares. The stock had previously closed at $49.14.

Analyst Ratings Changes

Several research firms have recently weighed in on BMY. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $61.18.

Bristol-Myers Squibb Trading Down 0.3 %

The business’s 50-day moving average price is $51.22 and its 200 day moving average price is $51.31. The company has a market cap of $99.03 billion, a P/E ratio of 12.66, a P/E/G ratio of 1.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.82 EPS. As a group, analysts expect that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.91%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Institutional Trading of Bristol-Myers Squibb

Hedge funds and other institutional investors have recently modified their holdings of the stock. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb in the 3rd quarter valued at about $27,000. Northwest Financial Advisors acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. Finally, Accordant Advisory Group Inc acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at approximately $31,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.